Summit Therapeutics

Perfil de la empresa

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis for the treatment of non-small lung cancer (NSCLC) and colorectal cancer (CRC). The company has also combined ivonescimab with chemotherapy, which is in phase III clinical trial for the patients with epidermal growth factor receptor, mutated, and locally advanced or metastatic non-squamous NSCLC; first-line metastatic NSCLC; and first-line unresectable metastatic CRC. It markets its products in the United states, Canada, Europe, Japan, Latin America, Middle East, and Africa. The company was founded in 2003 and is headquartered in Miami, Florida.

Descripción disponible en inglés.

Datos societarios

Sector

Salud

Industria

Biotechnology

País

Estados Unidos

Sede

601 Brickell Key Drive, 33131, Miami

Empleados

265

Cotización

SMMT · NASDAQ

Divisa

USD

Sitio web

smmttx.com